Tag: Enters

CubiCasa, a global-reaching real estate software company headquartered in Oulu, Finland, has announced a partnership with Bladescenes, a leading creative marketing agency for real estate located in Auckland, New Zealand. This partnership marks a notable boost to CubiCasa’s ongoing expansion into the Australian and New Zealand real estate markets, accelerating the global growth of its mobile property scanning technology. Bladescenes offers creative photography, videography, and now virtual floor plans as a part of its agency services. Bladescenes markets homes by capturing their prepossessing architect and layout potential through the use of digital technology. CubiCasa’s mobile capture technology gives Bladescenes’ customers ... Read more

XTS Technologies Sdn. Bhd. (XTS), a leading specialist in the design and build of factory automation solutions, and Huawei Technologies (M) Sdn. Bhd. (Huawei), a leading global provider of information and communications technology (ICT) infrastructure and smart devices, has signed a Memorandum of Understanding (MoU) with Padini Dot Com Sdn. Bhd., a subsidiary of Padini Holdings Berhad (Padini, Bursa: Main, 7052) for a warehouse automation solution using automated guided vehicles (AGVs) valued at RM1 million to be delivered within one year of a confirmed order. Top 1st row, R: Mr. Lim Chee Siong, Huawei Malaysia’s VP of the Cloud and ... Read more

Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant’s Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai’s U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent. H3B-8800 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1), discovered by H3 Biomedicine Inc. Splicing occurs to remove introns that are base sequence of pre-messenger RNA (mRNA), ... Read more

Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia (South Korea, Taiwan, Hong Kong and Singapore). In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the distribution and co-promotion of filgotinib in Japan. Under the terms of the new agreement, Eisai will obtain an exclusive marketing right for filgotinib in South Korea, Taiwan, Hong Kong ... Read more

 SnapCheck, the multi-award platform for business payments modernization, today announced that it has entered into a definitive agreement to be acquired. The buyer is an investment group aligned exclusively with Payroc World Access. By combining the transformative SnapCheck platform with Payroc’s recently acquired ACHeck21 Fintech Cloud solution, the buyer foresees the emergence of an entirely new dimension in payments. SnapCheck is a high speed, highly secure, and universally accepted solution dedicated to eliminating paper checks. Created as an open-ecosystem platform for paying anyone anywhere with the familiar form of a check, but without all the problems inherent in paper, the ... Read more